ArticleDermatology and therapy2026

Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.

Toshiyuki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.